DUNCAN BARBARA GAYLE
SEC insider (Form 3/4/5 filer). CIK 0001353128. Director at Atea Pharmaceuticals, Inc. (AVIR) and 2 other issuers. 11 reported Form 4/5 transactions since Sep 2024; latest on Jun 18, 2026. Located in BOSTON, MA.
Companies DUNCAN BARBARA GAYLE has filed insider reports for
- Atea Pharmaceuticals, Inc. (AVIR): Director
- HALOZYME THERAPEUTICS, INC. (HALO): Director
- Ovid Therapeutics Inc. (OVID): Director
DUNCAN BARBARA GAYLE
CIK: 0001353128
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (11 total)
- Jun 18, 2026AVIR
Atea Pharmaceuticals, Inc.
AwardDirectRestricted Stock Units
26.7K shares- - Jun 18, 2026AVIR
Atea Pharmaceuticals, Inc.
ExerciseDirect29.6K shares- - Jun 18, 2026AVIR
Atea Pharmaceuticals, Inc.
AwardDirectStock Option (Right to Buy)
37.7K shares- - May 5, 2026HALO
HALOZYME THERAPEUTICS, INC.
AwardDirect3.8K shares- - Feb 26, 2026OVID
Ovid Therapeutics Inc.
AwardDirectEmployee Stock Option (Right to Buy)
65K shares- - Jun 20, 2025AVIR
Atea Pharmaceuticals, Inc.
AwardDirectStock Option (Right to Buy)
41.2K shares- - Jun 20, 2025AVIR
Atea Pharmaceuticals, Inc.
ExerciseDirect29.6K shares- - Jun 20, 2025AVIR
Atea Pharmaceuticals, Inc.
AwardDirectRestricted Stock Units
29.6K shares- - May 1, 2025HALO
HALOZYME THERAPEUTICS, INC.
AwardDirect4.2K shares- - Feb 20, 2025OVID
Ovid Therapeutics Inc.
AwardDirectStock Option (right to buy)
45K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 18, 2026 |  AVIR Atea Pharmaceuticals, Inc. | Award Restricted Stock Units | 26,700 | - | - | Direct |
| Jun 18, 2026 | AVIR Atea Pharmaceuticals, Inc. | Exercise | 29,600 | - | $0 | Direct |
| Jun 18, 2026 | AVIR Atea Pharmaceuticals, Inc. | Award Stock Option (Right to Buy) | 37,700 | - | - | Direct |
| May 5, 2026 |  HALO HALOZYME THERAPEUTICS, INC. | Award | 3,796 | - | $0 | Direct |
| Feb 26, 2026 |  OVID Ovid Therapeutics Inc. | Award Employee Stock Option (Right to Buy) | 65,000 | - | - | Direct |
| Jun 20, 2025 | AVIR Atea Pharmaceuticals, Inc. | Award Stock Option (Right to Buy) | 41,200 | - | - | Direct |
| Jun 20, 2025 | AVIR Atea Pharmaceuticals, Inc. | Exercise | 29,600 | - | - | Direct |
| Jun 20, 2025 | AVIR Atea Pharmaceuticals, Inc. | Award Restricted Stock Units | 29,600 | - | - | Direct |
| May 1, 2025 | HALO HALOZYME THERAPEUTICS, INC. | Award | 4,165 | - | - | Direct |
| Feb 20, 2025 | OVID Ovid Therapeutics Inc. | Award Stock Option (right to buy) | 45,000 | - | - | Direct |
1-10 of 11 transactions